You are viewing an expired study
This study is not currently recruiting Study Participants on If you would like to find active studies please search for clinical trials

Birmingham, Alabama

  • Postmenopausal Osteoporosis


Effects of Teriparatide in Postmenopausal Women Previously Treated with Alendronate or Raloxifene.


Inclusion Criteria: - Postmenopausal women aged at least 50 years - A previous clinical diagnosis of osteoporosis - At high risk for fracture - Current therapy for at least 18 months prior to study entry with either raloxifene HCl or alendronate Na Exclusion Criteria: - History of metabolic bone disease other than osteoporosis - History of malignant neoplasm within the last 5 years except for superficial basal cell carcinoma or squamous cell carcinoma

Study is Available At:

Original ID:




Secondary ID:


Study Acronym:

Brief Title:

Effects of Teriparatide in Postmenopausal Women With Osteoporosis

Official Title:

Effects of Teriparatide in Postmenopausal Women With Osteoporosis Previously Treated With Alendronate or Raloxifene

Overall Status:


Study Phase:

Phase 4



Minimum Age:

50 Years

Maximum Age:


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Eli Lilly and Company

Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Allocation: Randomized, Endpoint Classification:

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:

Overall Contact Information

Official Name:Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
Study Director
Eli Lilly and Company

Study Dates

Start Date:November 2004
Completion Date:May 2007
Completion Type:Actual
Verification Date:May 2007
Last Changed Date:May 23, 2007
First Received Date:March 18, 2004

Study Outcomes

Outcome Type:Secondary Outcome
Measure:Frequency of hypercalcemia, various calcium assessments, change in bone mineral density and tests of bone formation and resorption
Safety Issues:False
Outcome Type:Primary Outcome
Measure:Change in calcium values after beginning teriparatide
Safety Issues:False

Study Interventions

Intervention Type:Drug
Intervention Type:Drug
Intervention Type:Drug

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Eli Lilly and Company

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source:

Date Processed: March 30, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.